Adult Social CareAlzheimer'sCareCare HomesCare ProvidersDementiaHealthcareHomecareNewsNursing HomesResearchSocial Care

New Alzheimer’s Drug Shows Promise in Trial, But Benefits Vary Across Patients

An experimental once-daily tablet being developed as a potential treatment for early Alzheimer’s disease has produced encouraging results in a late-stage clinical trial, although its apparent benefits were not demonstrated across the entire study population.

The drug, known as AR1001, was associated with a 31% slowing in the deterioration of memory and thinking abilities over 12 months among a subgroup of participants who were not taking other Alzheimer’s medications.

However, the results from the full trial population did not demonstrate a statistically significant improvement compared with placebo, highlighting the need for further research before the treatment’s potential can be established.

The findings were announced by South Korean pharmaceutical developer AriBio on 16 November at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston.

The international Phase 3 POLARIS-AD study involved 1,535 people with early-stage Alzheimer’s disease, recruited through approximately 230 research centres across 13 countries.

Researchers examined the effects of AR1001 in participants who were already receiving established Alzheimer’s treatments, as well as those who were not taking other medication for the condition when they entered the trial.

Of the total participants, 604 were not taking cholinesterase inhibitors, such as donepezil, or memantine at the beginning of the study. It was within this group that the most encouraging results were recorded.

After 52 weeks, participants receiving AR1001 experienced a smaller deterioration in their condition than those given a placebo, with a difference of 0.44 points on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale.

AriBio calculated this represented a 31% reduction in the rate of decline compared with placebo. The company said the result was statistically significant and met the study’s primary objective for this pre-defined group.

The picture was less encouraging when all 1,535 participants were considered together. Across the full trial population, the difference between AR1001 and placebo was 0.11 points on the same scale, equivalent to an estimated 7% slowing of decline. This result did not reach statistical significance.

The findings suggest that the treatment’s potential effectiveness may depend on whether patients are also receiving existing Alzheimer’s medications, an issue researchers will need to investigate further.

The CDR-SB assessment is widely used in Alzheimer’s research to measure changes in a person’s cognitive abilities and everyday functioning. It considers six areas, including memory, judgement, personal care and the ability to manage activities at home. Higher scores indicate greater impairment.

Additional assessments in the group not taking other Alzheimer’s medication also produced mixed results. Participants receiving AR1001 recorded a statistically significant difference of 0.7 points compared with placebo on the Mini-Mental State Examination (MMSE), which assesses memory and cognitive function.

However, another measure, the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), did not show a statistically significant difference.

Researchers also reported increased levels of cyclic guanosine monophosphate (cGMP) in spinal fluid among participants receiving AR1001. This is consistent with the drug’s intended biological mechanism, although further evidence will be needed to establish how this relates to any clinical benefit.

AR1001 is being investigated as a potential disease-modifying treatment, with a different approach from established medicines used to manage Alzheimer’s symptoms.

Commenting on the findings, Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, said the results offered an encouraging indication that a new approach to treating early Alzheimer’s disease could be emerging.

He highlighted the drug’s proposed action on blood vessels and brain circulation, as well as the potential advantages of a once-daily tablet compared with treatments requiring more complex administration.

Dr Oakley also stressed that the findings needed to be interpreted carefully, particularly given the lack of a statistically significant benefit across the entire trial population and the apparent differences between participants taking and not taking other Alzheimer’s medications.

He noted that the reported side effects were predominantly mild to moderate, while emphasising that the treatment was not yet available to patients.

AR1001 would need to undergo further assessment and receive the necessary regulatory approvals before it could be prescribed in the UK.

Dr Oakley said the latest findings reinforced the importance of continued investment in dementia research and the development of new treatment options. He also underlined the importance of obtaining an early and accurate diagnosis, enabling people with dementia to access appropriate support and potentially benefit from future advances in treatment.

Alzheimer’s disease remains the most common form of dementia, and the search for treatments capable of slowing its progression continues to be a major focus of international research.

 

Nescafe26Blue